GSK1265744 10 mg oral solution + GSK1265744 5 mg tablet + GSK1265744 5 mg tablet
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
HIV Infection
Conditions
HIV Infection, Infection, Human Immunodeficiency Virus
Trial Timeline
Jun 1, 2008 → Aug 1, 2008
NCT ID
NCT00812318About GSK1265744 10 mg oral solution + GSK1265744 5 mg tablet + GSK1265744 5 mg tablet
GSK1265744 10 mg oral solution + GSK1265744 5 mg tablet + GSK1265744 5 mg tablet is a phase 1 stage product being developed by Shionogi for HIV Infection. The current trial status is completed. This product is registered under clinical trial identifier NCT00812318. Target conditions include HIV Infection, Infection, Human Immunodeficiency Virus.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00812318 | Phase 1 | Completed |
Competing Products
20 competing products in HIV Infection